Literature DB >> 27648636

Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains.

Jian Zhou1, Fan Yang1, Jinghui Yang1,2, Lei Ma1, Yina Cun1, Shaohui Song1, Guoyang Liao1.   

Abstract

Vaccination is the practiced and accessible measure for preventing influenza infection. Because chicken embryos used for vaccine production have various insufficiencies, more efficient methods are needed. African green monkey kidney (Vero) cells are recommended by the World Health Organization (WHO) as a safe substitute for influenza vaccine production for humans. However, the influenza virus usually had low-yield in Vero cells, which limits the usage of Vero cellular vaccines. This study used 2 high-yield influenza viruses in Vero cells: A/Yunnan/1/2005Va (H3N2) and B/Yunnan/2/2005Va (B) as donor viruses. It used 3 wild strain viruses to reassort new adaptation viruses, including: A/Tianjin/15/2009(H1N1), A/Fujian/196/2009(H3N2), and B/Chongqing/1384/2010(B). These three new viruses could maintain the characteristic of high-yield in Vero cells. Furthermore, they could keep the immunogenic characteristics of the original wild influenza viruses. Importantly, these viruses were shown as safe in chicken embryo and guinea pigs assessment systems. These results provide an alternative method to produce influenza vaccine based on Vero cells.

Entities:  

Keywords:  Vero cells; influenza virus; reassortant; safety assessment

Mesh:

Substances:

Year:  2016        PMID: 27648636      PMCID: PMC5287297          DOI: 10.1080/21645515.2016.1231261

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  14 in total

1.  Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.

Authors:  Koert J Stittelaar; Edwin J B Veldhuis Kroeze; Larisa Rudenko; Rajeev Dhere; Sit Thirapakpoomanunt; Marie Paule Kieny; Albert D M E Osterhaus
Journal:  Vaccine       Date:  2011-09-22       Impact factor: 3.641

2.  Vaccine preparedness--are we ready for the next influenza pandemic?

Authors:  Peter F Wright
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

3.  Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Authors:  Larry R Smith; Walter Wodal; Brian A Crowe; Astrid Kerschbaum; Peter Bruehl; Michael G Schwendinger; Helga Savidis-Dacho; Sean M Sullivan; Mark Shlapobersky; Jukka Hartikka; Alain Rolland; P Noel Barrett; Otfried Kistner
Journal:  Hum Vaccin Immunother       Date:  2013-03-06       Impact factor: 3.452

4.  Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

Authors:  Maikel V W van der Velden; Richard Fritz; Eva Maria Pöllabauer; Daniel Portsmouth; M Keith Howard; Thomas R Kreil; Thomas Dvorak; Sandor Fritsch; Timo Vesikari; Javier Diez-Domingo; Peter Richmond; Bee Wah Lee; Otfried Kistner; Hartmut J Ehrlich; P Noel Barrett; Gerald Aichinger
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

5.  Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Authors:  Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

6.  Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.

Authors:  N Sugaya; K Nerome; M Ishida; M Matsumoto; K Mitamura; M Nirasawa
Journal:  JAMA       Date:  1994-10-12       Impact factor: 56.272

7.  The expression of essential components for human influenza virus internalisation in Vero and MDCK cells.

Authors:  Maharani Ugiyadi; Marselina I Tan; Ernawati A Giri-Rachman; Fawzi R Zuhairi; Sony H Sumarsono
Journal:  Cytotechnology       Date:  2013-08-04       Impact factor: 2.058

8.  Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.

Authors:  Alex B Ryder; Raffael Nachbagauer; Linda Buonocore; Peter Palese; Florian Krammer; John K Rose
Journal:  J Virol       Date:  2015-12-16       Impact factor: 5.103

9.  Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge.

Authors:  Xiaolan Yang; Jianyu Zhao; Cheng Wang; Yueqiang Duan; Zhongpeng Zhao; Rui Chen; Liangyan Zhang; Li Xing; Chengcai Lai; Shaogeng Zhang; Xiliang Wang; Penghui Yang
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

10.  Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.

Authors:  Xiaoqing Liu; Yuan Liu; Yanjun Zhang; Zhihui Chen; Ziwei Tang; Qingqiang Xu; Yue Wang; Ping Zhao; Zhongtian Qi
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more
  4 in total

1.  Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method.

Authors:  Yunfeng Long; Lei Ma; Ze Liu; Shaohui Song; Xingliang Geng; Fan Yang; Qi Guo; Zhuofan Li; Weidong Li; Guoyang Liao
Journal:  Hum Vaccin Immunother       Date:  2017-10-31       Impact factor: 3.452

Review 2.  Virological and Immunological Outcomes of Coinfections.

Authors:  Naveen Kumar; Shalini Sharma; Sanjay Barua; Bhupendra N Tripathi; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2018-07-05       Impact factor: 26.132

3.  Construction and identification of influenza plasmid pool imparting high yields to candidate vaccine viruses in Vero cell at low temperature.

Authors:  Ze Liu; Xingliang Geng; Zhaohai Cui; Weidong Li; Xia Ou; Guoyang Liao
Journal:  J Cell Mol Med       Date:  2020-09-09       Impact factor: 5.310

4.  Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness.

Authors:  Po-Ling Chen; Tsai-Teng Tzeng; Alan Yung-Chih Hu; Lily Hui-Ching Wang; Min-Shi Lee
Journal:  Vaccines (Basel)       Date:  2020-10-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.